QC

Impending Strike Threatens In-Flight Meals for Travelers Departing Pearson Airport: Teamsters Union

Retrieved on: 
Tuesday, April 9, 2024
Cooking, TAP Air Portugal, Teamsters Canada, Safety, Toronto Pearson International Airport, Air Canada, Transport, Air India, Scandinavian Airlines, Paramount, Drink, Snack, Delta Air Lines, Gategroup, Canada Jetlines, Food industry, Clothing

The workers are tasked with cooking, packing and delivering meals, snacks, beverages, and other supplies to planes for in-flight service.

Key Points: 
  • The workers are tasked with cooking, packing and delivering meals, snacks, beverages, and other supplies to planes for in-flight service.
  • A strike at the company could mean no food and beverages on many flights out of Toronto Pearson Airport this month.
  • We're going on strike unless this company steps up to the plate and finally acknowledges how expensive life has gotten,” said lead union negotiator and president of Teamsters Local Union 647, Martin Cerqua.
  • They are affiliated with the International Brotherhood of Teamsters, which represents over 1.2 million workers in North America.

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Tuesday, April 9, 2024
Metro Toronto Convention Centre, GUD, TSX, Conference

MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m.

Key Points: 
  • MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m.
  • ET at the Metro Toronto Convention Centre in Toronto.
  • A copy of the presentation will be available at www.knighttx.com .

Goodfood to Report Second Quarter of Fiscal Year 2024 Results

Retrieved on: 
Tuesday, April 9, 2024
FOOD, Conference call, Conference, TSX, Fiscal, CFO

MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Goodfood Market Corp. (“Goodfood” or “the Company”) (TSX:FOOD), a leading Canadian online meal solutions company, will release its financial results for the second quarter of Fiscal 2024 on Tuesday, April 16, 2024, before markets open.

Key Points: 
  • MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Goodfood Market Corp. (“Goodfood” or “the Company”) (TSX:FOOD), a leading Canadian online meal solutions company, will release its financial results for the second quarter of Fiscal 2024 on Tuesday, April 16, 2024, before markets open.
  • Jonathan Ferrari, CEO, Neil Cuggy, President and COO, and Roslane Aouameur, CFO, will hold a conference call to review the results at 8:00 a.m. (ET).
  • Details of the Earnings Conference Call:
    Conference call replay available until April 23, 2024:

Premier Health Announces the Appointment of Bruno Morel as its New CTO

Retrieved on: 
Monday, April 8, 2024
PHA, Health, Corporation, App Store (iOS/iPadOS), AI, DevOps, Management

MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Health tech company, announces the appointment of Bruno Morel as the Corporation’s new Chief Technology Officer, effective immediately.

Key Points: 
  • MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Health tech company, announces the appointment of Bruno Morel as the Corporation’s new Chief Technology Officer, effective immediately.
  • “We are very excited to have Bruno join Premier Health.
  • Bruno has over 20 years of experience building complex software and managing development and operation teams in fast developing technology companies.
  • Current Chief Technology Officer Éric Dupont, who joined Premier Health in December 2021, will continue with the Corporation for a transition period.

Gildan Activewear Announces Investor Update on April 15, 2024

Retrieved on: 
Monday, April 8, 2024
GIL, TSX

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or “the Company”) today announces that its President and CEO, Vince Tyra, will provide an Investor Update in an upcoming webcast event on April 15, 2024, marking his first 90 days at Gildan.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or “the Company”) today announces that its President and CEO, Vince Tyra, will provide an Investor Update in an upcoming webcast event on April 15, 2024, marking his first 90 days at Gildan.
  • Vince was appointed President and CEO on December 11, 2023, and assumed his new position on January 15, 2024.
  • The event will take place on April 15, 2024, at 4:45 PM ET.
  • A live audio webcast of the conference call and presentation, as well as a replay, will be available at the following link: Gildan Investor Update.

Brunswick Signs Right to Repurchases 0.5% NSR on Select Claims at Mirage

Retrieved on: 
Monday, April 8, 2024
Mirage, BRW, OTCQB, TSX, Lithium, NSR, Teahouse

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to announce that it signed an agreement with Sirios Resources (“Sirios”) to repurchase an existing 0.5% NSR on certain claims within the Mirage Project, located in the Eeyou Istchee James Bay region of Quebec.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to announce that it signed an agreement with Sirios Resources (“Sirios”) to repurchase an existing 0.5% NSR on certain claims within the Mirage Project, located in the Eeyou Istchee James Bay region of Quebec.
  • Mr. Killian Charles, President and CEO of BRW, commented: “We are excitedly looking forward to the approaching release of the first wave of results from our Winter 2024 campaign at Mirage as these results will continue to demonstrate the growing exploration prospectivity at Mirage.
  • The payment schedule is subject to the following constraints:
    Share amount is calculated on the 10-day Volume Weighted Average Share Price preceding the date of the payment and is subject to a $0.40 minimum share price.
  • Upon start of mineral extraction over the claims covered by this agreement, Brunswick will make a further milestone payment to Sirios of $250,000 in cash or an amount in shares (share amount is calculated on the 10-day Volume Weighted Average Share Price preceding the date of the payment and is subject to a $0.40 minimum share price) or a combination of both, at Brunswick’s discretion.

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Retrieved on: 
Monday, April 8, 2024
Gene silencing, Irinotecan, Colorectal cancer, Immunotherapy, Triple-negative breast cancer, Mouse, Observation, Endocytosis, Cancer, Christian democracy, SN-38, Senior, Camptothecin, Conjugation, AACR, TSX, Treatment, Neoplasm, CRC, Poster, HT-29, TNBC, PDC, Vaccine

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.
  • The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads.
  • “In addition to our lead peptide-drug conjugate, sudocetaxel zendusortide, these latest data highlight the promising tolerability and anti-tumor effects of our investigational camptothecin-peptide conjugates, further demonstrating the versatility and flexibility of the platform.
  • In the poster presented at AACR, the investigators noted that SORT1 gene silencing inhibits camptothecin-conjugate uptake in human HT-29 colorectal adenocarcinoma cells.

Osisko Announces Q1 2024 Geo Deliveries and Select Asset Updates

Retrieved on: 
Monday, April 8, 2024
Odyssey, Mining, Copper, Australian Securities Exchange, Osisko Gold Royalties, Silver, SSRP, GEOS, SAG, Gold, Senate, Annual report, Corporation, ASX, Acquisition, Mineral, Refused, CSA, Abitibi, Agnico Eagle, Ventilation, NSR, Resource

In addition, Osisko is excited to provide some select asset updates.

Key Points: 
  • In addition, Osisko is excited to provide some select asset updates.
  • Osisko earned 22,259 attributable gold equivalent ounces1 (“GEOs”) in the first quarter of 2024.
  • Osisko owns a 2% NSR royalty on the Ermitaño project and the Cumobabi property, including the Luna and Soledad Zones.
  • Osisko provides notice of the first quarter 2024 results and conference and webcast call details.

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

Retrieved on: 
Monday, April 8, 2024
Karolinska University Hospital, EudraCT, PD, L-DOPA, Patient, IGX, Doctor of Philosophy, MD, TSX, Clinical trial, Pharmaceutical industry

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.

Key Points: 
  • SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.
  • MONTPARK (EudraCT number 2023-504278-39-00) is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD.
  • The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period.
  • Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents.

Boralex will release its 2024 first quarter financial results on May 15

Retrieved on: 
Monday, April 8, 2024
PIN, TSX, BLX, Boralex

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Boralex inc. (“Boralex” or the “Company”) (TSX: BLX) announces that the release of the 2024 first quarter results will take place on Wednesday, May 15, 2024, at 9 a.m.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Boralex inc. (“Boralex” or the “Company”) (TSX: BLX) announces that the release of the 2024 first quarter results will take place on Wednesday, May 15, 2024, at 9 a.m.
    Financial analysts and investors are invited to attend a conference call during which the financial results will be presented.
  • To attend the event by phone: Click here to register for the earnings call.
  • A full replay will also be available on Boralex’s website until May 15, 2025.
  • The financial information will be released through a press release and on Boralex's website on May 15, 2024, at 7 a.m.